1
|
Association of serum level of chemerin with visceral fat obesity in type 2 diabetic patient. Int J Diabetes Dev Ctries 2022. [DOI: 10.1007/s13410-022-01066-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
2
|
Xie Y, Liu L. Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction. J Transl Med 2022; 20:141. [PMID: 35317838 PMCID: PMC8939091 DOI: 10.1186/s12967-021-03220-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 12/27/2021] [Indexed: 02/08/2023] Open
Abstract
Sufficient epidemiological investigations demonstrate that there is a close correlation between obesity and vascular dysfunction. Nevertheless, specific mechanisms underlying this link remain currently unclear. Given the crucial and decisive role of vascular dysfunction in multitudinous diseases, various hypotheses had been proposed and numerous experiments were being carried out. One recognized view is that increased adipokine secretion following the expanded mass of white adipose tissue due to obesity contributes to the regulation of vascular function. Chemerin, as a neo-adipokine, whose systemic level is elevated in obesity, is believed as a regulator of adipogenesis, inflammation, and vascular dysfunction via binding its cell surface receptor, chemR23. Hence, this review aims to focus on the up-to-date proof on chemerin/chemR23 axis-relevant signaling pathways, emphasize the multifarious impacts of chemerin/chemR23 axis on vascular function regulation, raise certain unsettled questions to inspire further investigations, and explore the therapeutic possibilities targeting chemerin/chemR23.
Collapse
Affiliation(s)
- Yingying Xie
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.,Research Institute of Blood Lipid and Atherosclerosis, Central South University, Changsha, China.,Modern Cardiovascular Disease Clinical Technology Research Center of Hunan Province, Changsha, China.,Cardiovascular Disease Research Center of Hunan Province, Changsha, China
| | - Ling Liu
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China. .,Research Institute of Blood Lipid and Atherosclerosis, Central South University, Changsha, China. .,Modern Cardiovascular Disease Clinical Technology Research Center of Hunan Province, Changsha, China. .,Cardiovascular Disease Research Center of Hunan Province, Changsha, China.
| |
Collapse
|
3
|
Li X, Sun M, Yang Y, Yao N, Yan S, Wang L, Hu W, Guo R, Wang Y, Li B. Predictive Effect of Triglyceride Glucose-Related Parameters, Obesity Indices, and Lipid Ratios for Diabetes in a Chinese Population: A Prospective Cohort Study. Front Endocrinol (Lausanne) 2022; 13:862919. [PMID: 35432185 PMCID: PMC9007200 DOI: 10.3389/fendo.2022.862919] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Accepted: 02/25/2022] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVE The purpose of this study was to evaluate the association between triglyceride glucose (TyG) index and new-onset diabetes under different glycemic states and to compare the predictive value of TyG-related parameters, obesity indices, and lipid ratios for new-onset diabetes. METHODS Data were collected from the China Health and Retirement Longitudinal Study (CHARLS), consisting of 6,258 participants aged ≥45 years. Participants were grouped according to their glycemic states. Cox proportional hazards models and restricted cubic spline regression were used to explore the association between TyG index and diabetes. Cox proportional hazard models were applied to confirm the predictive value of the optimal marker. Receiver operating characteristic (ROC) curves were used to compare the predictive value. RESULTS TyG index was positively correlated with the risk of diabetes (hazard ratio (HR), 1.75; 95% confidence interval (CI), 1.56-1.97), and the linear association existed (p < 0.001). The highest correlation with diabetes was visceral adiposity index (VAI) (HR, 2.04; 95% CI, 1.44-2.90) in normal fasting glucose (NFG) group and TyG-body mass index (TyG-BMI) (HR, 2.53; 95% CI, 1.97-3.26) in impaired fasting glucose (IFG) group. The largest area under curve (AUC) was observed in TyG-waist-to-height ratio (TyG-WHtR) in the NFG group (AUC, 0.613; 95% CI, 0.527-0.700), and TyG-BMI had the highest AUC in the IFG group (AUC, 0.643; 95% CI, 0.601-0.685). CONCLUSION The association between TyG index and new-onset diabetes was positive and linear. TyG-WHtR was a clinically effective marker for identifying the risks of diabetes in the NFG group and TyG-BMI was an effective marker to predict diabetes in the IFG group.
Collapse
|
4
|
Susairaj P, Snehalatha C, Nanditha A, Satheesh K, Raghavan A, Vinitha R, Ramachandran A. Analysis of an Indian diabetes prevention programme on association of adipokines and a hepatokine with incident diabetes. Sci Rep 2021; 11:20327. [PMID: 34645898 PMCID: PMC8514464 DOI: 10.1038/s41598-021-99784-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 09/27/2021] [Indexed: 12/22/2022] Open
Abstract
To study the association and possible predictive role of visfatin, resistin, fetuin-A and chemerin with incident type 2 diabetes (T2DM) among Asian Indians with prediabetes. Their association with insulin resistance, β-cell function, glycaemia and anthropometry were also studied. This is a nested case-control study of a large 2-year prospective prevention trial in persons at high risk of developing T2DM. Baseline HbA1c values between 6.0% (42 mmol/mol) and 6.2% (44 mmol/mol) were chosen for this analysis (n = 144). At follow-up, persons with incident T2DM (HbA1c ≥ 6.5%, 48 mmol/mol) were grouped as cases (n = 72) and those reverted to normoglycaemia, (HbA1c < 5.7% (39 mmol/mol) as controls (n = 72). Insulin resistance showed the strongest association with incident T2DM ((Odds Ratio (OR): 23.22 [95%CI 6.36-84.77]; p < 0.0001). Baseline visfatin (OR: 6.56 [95%CI 2.21-19.5]; p < 0.001) and fetuin-A (OR: 1.01 [95%CI (1.01-1.04)]; p < 0.0001) independently contributed to the conversion of prediabetes to T2DM. The contribution was significantly higher when their elevated levels coexisted (OR: 12.63 [95%CI 3.57-44.63]; p < 0.0001). The area under the curve was 0.77 ± SE 0.4 (95%CI 0.69-0.85) and 0.80 ± SE 0.04 (95%CI 0.73-0.88) for visfatin (median 17.7 ng/ml, sensitivity and specificity: 75%, p < 0.0001) and fetuin-A (mean 236.2 µg/ml, sensitivity: 71%, specificity: 75%, p < 0.0001) respectively. Higher baseline visfatin and fetuin-A concentrations are strongly associated with incident T2DM and are predictive of future diabetes.
Collapse
Affiliation(s)
- Priscilla Susairaj
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India
| | - Chamukuttan Snehalatha
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India
| | - Arun Nanditha
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India
| | - Krishnamoorthy Satheesh
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India
| | - Arun Raghavan
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India
| | - Ramachandran Vinitha
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India
| | - Ambady Ramachandran
- India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, 110, Anna Salai, Guindy, Chennai, 600 032, India.
| |
Collapse
|
5
|
Gonzalez-Ponce F, Gamez-Nava JI, Perez-Guerrero EE, Saldaña-Cruz AM, Vazquez-Villegas ML, Ponce-Guarneros JM, Huerta M, Trujillo X, Contreras-Haro B, Rocha-Muñoz AD, Carrillo-Escalante MO, Sanchez-Rodriguez EN, Gomez-Ramirez EE, Nava-Valdivia CA, Cardona-Muñoz EG, Gonzalez-Lopez L. Serum chemerin levels: A potential biomarker of joint inflammation in women with rheumatoid arthritis. PLoS One 2021; 16:e0255854. [PMID: 34506500 PMCID: PMC8432803 DOI: 10.1371/journal.pone.0255854] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Accepted: 07/24/2021] [Indexed: 11/18/2022] Open
Abstract
Background Chemerin has a potential role in perpetuating inflammation in autoimmune diseases. Nevertheless, to date, there is no conclusive information on whether high chemerin levels increase the severity of rheumatoid arthritis (RA). Therefore, this study evaluated whether serum chemerin is a biomarker of disease activity in RA patients. Methods Study design: cross-sectional. The assessment included clinical and laboratory characteristics, body mass index (BMI) and fat mass. The severity of the disease activity was identified according to the DAS28-CRP index as follows: A) RA with a DAS28-CRP≤2.9 (remission/mild activity) and B) RA with a DAS28-CRP>2.9 (moderate/severe activity). Serum chemerin concentrations were measured by ELISA, and ≥103 ng/mL was considered a high level. Logistic regression analysis was applied to determine whether high chemerin levels were associated with disease activity in RA after adjusting for confounders. Multiple regression analysis was performed to identify variables associated with chemerin levels. Results Of 210 RA patients, 89 (42%) subjects had moderate/severe disease activity and had higher serum chemerin levels than patients with low disease activity or remission (86 ± 34 vs 73± 27; p = 0.003). Serum chemerin correlated with the number of swollen joints (r = 0.15; p = 0.03), DAS28-CRP (r = 0.22; p = 0.002), and C-reactive protein levels (r = 0.14; p = 0.04), but no correlation was observed with BMI and fat mass. In the adjusted logistic regression analysis, high chemerin levels (≥103 ng/mL) were associated with an increased risk of moderate/severe disease activity (OR: 2.76, 95% CI 1.35–5.62; p = 0.005). In the multiple regression analysis, after adjusting for potential confounders, serum chemerin levels were associated with higher DAS28-CRP (p = 0.002). Conclusions Higher chemerin levels increased the risk of moderate and severe disease activity in RA. These results support the role of chemerin as a marker of inflammation in RA. Follow-up studies will identify if maintaining low chemerin levels can be used as a therapeutic target.
Collapse
Affiliation(s)
- Fabiola Gonzalez-Ponce
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Jorge I. Gamez-Nava
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Departamento de Salud Pública, Programa de Doctorado en Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Unidad de Investigación Biomédica 02, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
| | - Emilio E. Perez-Guerrero
- Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Ana M. Saldaña-Cruz
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Maria L. Vazquez-Villegas
- Departamento de Salud Pública, Programa de Doctorado en Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Servicio de Epidemiología, Unidad de Medicina Familiar número 04, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
| | - Juan M. Ponce-Guarneros
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Unidad Medica Familiar 97, Instituto Mexicano del Seguro Social, Magdalena, Jalisco, México
| | - Miguel Huerta
- Centro Universitario de Investigaciones Biomedicas, Universidad de Colima, Colima, Mexico
| | - Xochitl Trujillo
- Centro Universitario de Investigaciones Biomedicas, Universidad de Colima, Colima, Mexico
| | - Betsabe Contreras-Haro
- División de Ciencias de la Salud, Departamento de Ciencias Biomédicas, Departamento Salud-Enfermedad como Proceso Individual, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jalisco México
| | - Alberto D. Rocha-Muñoz
- División de Ciencias de la Salud, Departamento de Ciencias Biomédicas, Departamento Salud-Enfermedad como Proceso Individual, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jalisco México
| | - Maria O. Carrillo-Escalante
- Departamento de Salud Pública, Programa de Doctorado en Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Esther N. Sanchez-Rodriguez
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Eli E. Gomez-Ramirez
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Cesar A. Nava-Valdivia
- Departamento de Microbiologia y Patologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
| | - Ernesto G. Cardona-Muñoz
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- * E-mail: , (LGL); , (EGCM)
| | - Laura Gonzalez-Lopez
- Departamento de Fisiología Centro Universitario de Ciencias de la Salud, Programa de Doctorado en Farmacología, Instituto de Terapeutica Experimental y Clínica, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Departamento de Salud Pública, Programa de Doctorado en Salud Publica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico
- * E-mail: , (LGL); , (EGCM)
| | | |
Collapse
|
6
|
Ferland DJ, Mullick AE, Watts SW. Chemerin as a Driver of Hypertension: A Consideration. Am J Hypertens 2020; 33:975-986. [PMID: 32453820 PMCID: PMC7759724 DOI: 10.1093/ajh/hpaa084] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 05/06/2020] [Accepted: 05/20/2020] [Indexed: 12/13/2022] Open
Abstract
The protein chemerin (tazarotene-induced gene, TIG2; RARRES2) is a relatively new adipokine. Many studies support that circulating chemerin levels associate strongly and positively with body mass index, visceral fat, and blood pressure. Here, we focus on the specific relationship of chemerin and blood pressure with the goal of understanding whether and how chemerin drives (pathological) changes in blood pressure such that it could be interfered with therapeutically. We dissect the biosynthesis of chemerin and how current antihypertensive medications change chemerin metabolism. This is followed with a review of what is known about where chemerin is synthesized in the body and what chemerin and its receptors can do to the physiological function of organs important to blood pressure determination (e.g., brain, heart, kidneys, blood vessels, adrenal, and sympathetic nervous system). We synthesize from the literature our best understanding of the mechanisms by which chemerin modifies blood pressure, with knowledge that plasma/serum levels of chemerin may be limited in their pathological relevance. This review reveals several gaps in our knowledge of chemerin biology that could be filled by the collective work of protein chemists, biologists, pharmacologists, and clinicians.
Collapse
Affiliation(s)
- David J Ferland
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| | - Adam E Mullick
- Cardiovascular Antisense Drug Discovery, Ionis Pharmaceuticals, Carlsbad, California, USA
| | - Stephanie W Watts
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| |
Collapse
|
7
|
Sitar-Taut AV, Coste SC, Tarmure S, Orasan OH, Fodor A, Negrean V, Pop D, Zdrenghea D, Login C, Tiperciuc B, Cozma A. Diabetes and Obesity-Cumulative or Complementary Effects On Adipokines, Inflammation, and Insulin Resistance. J Clin Med 2020; 9:jcm9092767. [PMID: 32858998 PMCID: PMC7564772 DOI: 10.3390/jcm9092767] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 08/11/2020] [Accepted: 08/22/2020] [Indexed: 12/15/2022] Open
Abstract
Background: Diabetes and obesity are increasingly significant public health issues. The aim of this study was to evaluate the relationship between adipocytokines (leptin, ghrelin, and chemerin), inflammation (sVCAM1—soluble vascular adhesion molecule 1, sICAM1—soluble intercellular adhesion molecule 1), and insulin resistance in the presence of obesity and diabetes mellitus. Methods: 88 subjects, with a mean age of 61.96 ± 10.15 years, 75% of whom were women, were evaluated (in order to consider different associations between obesity and diabetes, subjects were categorized into four groups). Results: Overall, we found significant correlations between sICAM1-sVCAM1 rho = 0.426 and ghrelin-chemerin rho = −0.224. In the obesity + diabetes group, leptin correlated with sICAM1 rho = 0.786, and sVCAM1 negatively with glycemia/insulin rho = −0.85. Significant differences were found between the groups regarding sVCAM1 (p = 0.0134), leptin (p = 0.0265) and all insulin resistance scores, with differences influenced by the subjects’ gender. In conclusion, although there are currently many unknown aspects of the release and the role of various adipokines, in particular chemerin, its implication in early glucose metabolism dysregulation disorders seems very likely.
Collapse
Affiliation(s)
- Adela-Viviana Sitar-Taut
- Internal Medicine Department, 4th Medical Clinic “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (S.C.C.); (S.T.); (O.H.O.); (V.N.); (A.C.)
- Correspondence:
| | - Sorina Cezara Coste
- Internal Medicine Department, 4th Medical Clinic “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (S.C.C.); (S.T.); (O.H.O.); (V.N.); (A.C.)
| | - Simina Tarmure
- Internal Medicine Department, 4th Medical Clinic “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (S.C.C.); (S.T.); (O.H.O.); (V.N.); (A.C.)
| | - Olga Hilda Orasan
- Internal Medicine Department, 4th Medical Clinic “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (S.C.C.); (S.T.); (O.H.O.); (V.N.); (A.C.)
| | - Adriana Fodor
- Clinical Center of Diabetes, Nutrition, Metabolic diseases, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania;
| | - Vasile Negrean
- Internal Medicine Department, 4th Medical Clinic “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (S.C.C.); (S.T.); (O.H.O.); (V.N.); (A.C.)
| | - Dana Pop
- Department of Cardiology, Clinical Rehabilitation Hospital, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (D.P.); (D.Z.)
| | - Dumitru Zdrenghea
- Department of Cardiology, Clinical Rehabilitation Hospital, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (D.P.); (D.Z.)
| | - Cezar Login
- Department Physiology, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania;
| | - Brandusa Tiperciuc
- Department Pharmaceut Chem “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania;
| | - Angela Cozma
- Internal Medicine Department, 4th Medical Clinic “Iuliu Haţieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, CJ, Romania; (S.C.C.); (S.T.); (O.H.O.); (V.N.); (A.C.)
| |
Collapse
|
8
|
Analysis of serum chemerin concentrations in psoriatic patients in relation to metabolic abnormalities. Postepy Dermatol Alergol 2019; 36:531-537. [PMID: 31839769 PMCID: PMC6906971 DOI: 10.5114/ada.2019.89503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 07/19/2018] [Indexed: 11/17/2022] Open
Abstract
Introduction Recent data depict psoriasis as a systemic disease with many comorbidities, especially metabolic syndrome and cardiovascular diseases. Chemerin, an adipokine secreted by adipose tissue cells, may prove to be an important link between psoriasis and its comorbidities. Aim Assessment of serum concentrations of chemerin in patients with psoriasis and the healthy control group as well as evaluation of a possible correlation between adipokine concentrations and selected psoriasis severity indices and metabolic syndrome components. Material and methods One hundred and two patients with diagnosed psoriasis and 40 healthy volunteers were enrolled in the study. In all subjects, serum chemerin concentrations and selected metabolic syndrome components including lipid and glucose levels were determined. Psoriasis severity was assessed using the PASI and BSA indices. Results A higher concentration of chemerin was demonstrated in the group of psoriasis patients compared to the control group (p < 0.05). A positive correlation between chemerin concentration and C-reactive protein concentration (p = 0.001), body mass index (p = 0.031) and triglyceride concentration (p = 0.043) was found. An inverse correlation with high-density lipoprotein cholesterol concentrations (p = 0.015) was also noted. Significantly higher concentrations of chemerin were observed in psoriatic patients with elevated low-density lipoptotein (LDL) cholesterol levels in comparison with patients with normal LDL values (p = 0.032). Chemerin concentrations were also significantly higher in patients with both psoriasis and elevated glucose levels compared to patients with normal blood glucose values (p = 0.043). Conclusions The results obtained suggest a possible role of chemerin as an adipokine linking psoriasis with metabolic syndrome.
Collapse
|
9
|
Luo Y, Luo J, Peng H. Associations Between Genetic Polymorphisms in the VEGFA, ACE, and SOD2 Genes and Susceptibility to Diabetic Nephropathy in the Han Chinese. Genet Test Mol Biomarkers 2019; 23:644-651. [PMID: 31524543 DOI: 10.1089/gtmb.2018.0320] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Affiliation(s)
- Yuxuan Luo
- Department of Nephrology, Zhuji People's Hospital of Zhejiang Province, Zhuji, China
| | - Jingfeng Luo
- Biotherapy Center, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Hui Peng
- Department of Cardiology, Tongde Hospital of Zhejiang Province, Hangzhou, China
| |
Collapse
|
10
|
Fu YY, Hu BH, Chen KL, Li HX. Chemerin induces lipolysis through ERK1/2 pathway in intramuscular mature adipocytes of dairy bull calves. J Cell Biochem 2019; 120:1122-1132. [PMID: 30256444 DOI: 10.1002/jcb.27506] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Accepted: 07/18/2018] [Indexed: 01/24/2023]
Abstract
The adipokine Chemerin has been reported to regulate differentiation and metabolism of adipocytes, but the mechanism underlying lipolysis is still largely unknown. The purpose of this study was to explore whether ERK1/2 pathway is involved in regulating Chemerin during bovine intramuscular mature adipocyte lipolysis. Intramuscular mature adipocytes of dairy bull calves were cultured in vitro and were treated with Chemerin or U0126, which is an inhibitor of ERK1/2 pathway. The results showed that TG content in cells was significantly decreased, glycerol and free fatty acid were significantly increased in cell culture media, and the expression of phosphorylated ERK1/2 in cells was increased in Chemerin-treated group, suggested that ERK1/2 pathway was involved in regulation of lipolysis by Chemerin. In addition, the expression of lipolytic-related critical factors ATGL, HSL, LPL, PPARα, UCP3, and CPT1 were upregulated, but the expression of adipogenic key factors, including PPARγ and C/EBPα were downregulated by Chemerin. Interestingly, all the effects of Chemerin on genes expression in intramuscular mature adipocytes or fat tissue were inhibited by U0126, showed that the function of Chemerin to promote adipose decomposition will be significantly weakened if the ERK1/2 pathway is suppressed, and confirmed that ERK1/2 pathway is involved in mediate Chemerin-enhanced lipolysis. In conclusion, the study demonstrated that Chemerin induce intramuscular mature adipocytes lipolysis through activation of the ERK1/2 pathway. Our research at least provide partial mechanisms of Chemerin on lipolysis and deposition of intramuscular fat tissue of dairy bull calves.
Collapse
Affiliation(s)
- Yuan-Yuan Fu
- Department of Animal Genetics and Breeding, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - Bian-Hong Hu
- Department of Animal Genetics and Breeding, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - Kun-Lin Chen
- Department of Animal Genetics and Breeding, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| | - Hui-Xia Li
- Department of Animal Genetics and Breeding, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China
| |
Collapse
|
11
|
Akgul Balaban Y, Yilmaz N, Kalayci M, Unal M, Turhan T. IRISIN AND CHEMERIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. ACTA ENDOCRINOLOGICA-BUCHAREST 2019; 15:442-446. [PMID: 32377240 DOI: 10.4183/aeb.2019.442] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Context Changes in the secretion of signaling molecules that originates from adipose tissue and inflammation draw attention in the pathogenesis of type 2 DM. Chemerin, one of the signaling molecules of adipose origin, and irisin, defined as the Renaissance of the metabolism, are among these molecules. Objectives This cross-sectional study was planned in order to compare the values of serum irisin and chemerin levels in patients newly diagnosed with T2DM and in healthy subjects. Subjects and Methods The study included 41 patients newly diagnosed with T2DM and 49 healthy individuals. The chemistry parameters were analyzed with a biochemistry autoanalyzer, and hormonal parameters were analyzed with an immunoassay analyzer. Plasma irisin and chemerin levels were measured using the enzyme-linked immunosorbent assay method. Results There was a significant difference between the groups in terms of glucose, HbA1C, Insulin, HOMA-IR and lipid panel results. Irisin levels in the group of patients newly diagnosed with T2DM were lower than in the control group. Chemerin levels in the group of patients newly diagnosed with T2DM were higher than in the control group. Conclusion Consequently, diabetes-dependent changes in chemerin and irisin concentrations suggest that these two hormones have a role in the pathophysiology of DM. Further studies are required to understand the complex structure of the signaling pathways of chemerin and irisin molecules as well as the physiological importance of these molecules as metabolism regulators especially in humans.
Collapse
Affiliation(s)
- Y Akgul Balaban
- Mecitozu State Hospital - Internal Medicine, Corum, Ministry of Health Ankara City Hospital, Istanbul, Turkey
| | - N Yilmaz
- Internal Medicine, Istanbul, Turkey
| | - M Kalayci
- Elazig Fethi Sekin City Hospital - Medical Biochemistry, Elazig, Istanbul, Turkey
| | - M Unal
- Istinye University Medical Park Gaziosmanpasa - Endocrinology and Metabolism, Istanbul, Turkey
| | - T Turhan
- Medical Biochemistry, Ankara, Istanbul, Turkey
| |
Collapse
|
12
|
Watts SW, Darios ES, Mullick AE, Garver H, Saunders TL, Hughes ED, Filipiak WE, Zeidler MG, McMullen N, Sinal CJ, Kumar RK, Ferland DJ, Fink GD. The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension. FASEB J 2018; 32:fj201800479. [PMID: 29906243 PMCID: PMC6219827 DOI: 10.1096/fj.201800479] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Accepted: 05/21/2018] [Indexed: 12/30/2022]
Abstract
Measures of the adipokine chemerin are elevated in multiple cardiovascular diseases, including hypertension, but little mechanistic work has been done to implicate chemerin as being causative in such diseases. The chemerin knockout (KO) rat was created to test the hypothesis that removal of chemerin would reduce pressure in the normal and hypertensive state. Western analyses confirmed loss of chemerin in the plasma and tissues of the KO vs. wild-type (WT) rats. Chemerin concentration in plasma and tissues was lower in WT females than in WT males, as determined by Western analysis. Conscious male and female KO rats had modest differences in baseline measures vs. the WT that included systolic, diastolic, mean arterial and pulse pressures, and heart rate, all measured telemetrically. The mineralocorticoid deoxycorticosterone acetate (DOCA) and salt water, combined with uninephrectomy as a hypertensive stimulus, elevated mean and systolic blood pressures of the male KO higher than the male WT. By contrast, all pressures in the female KO were lower than their WT throughout DOCA-salt treatment. These results revealed an unexpected sex difference in chemerin expression and the ability of chemerin to modify blood pressure in response to a hypertensive challenge.-Watts, S. W., Darios, E. S., Mullick, A. E., Garver, H., Saunders, T. L., Hughes, E. D., Filipiak, W. E., Zeidler, M. G., McMullen, N., Sinal, C. J., Kumar, R. K., Ferland, D. J., Fink, G. D. The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.
Collapse
Affiliation(s)
- Stephanie W. Watts
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| | - Emma S. Darios
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| | | | - Hannah Garver
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| | - Thomas L. Saunders
- University of Michigan Transgenic Animal Model Core, University of Michigan, Ann Arbor, Michigan, USA
- Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Elizabeth D. Hughes
- University of Michigan Transgenic Animal Model Core, University of Michigan, Ann Arbor, Michigan, USA
| | - Wanda E. Filipiak
- University of Michigan Transgenic Animal Model Core, University of Michigan, Ann Arbor, Michigan, USA
| | - Michael G. Zeidler
- University of Michigan Transgenic Animal Model Core, University of Michigan, Ann Arbor, Michigan, USA
| | - Nichole McMullen
- Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
| | | | - Ramya K. Kumar
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| | - David J. Ferland
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| | - Gregory D. Fink
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan, USA
| |
Collapse
|
13
|
Fontes VS, Neves FS, Cândido APC. CHEMERIN AND FACTORS RELATED TO CARDIOVASCULAR RISK IN CHILDREN AND ADOLESCENTS: A SYSTEMATIC REVIEW. REVISTA PAULISTA DE PEDIATRIA : ORGAO OFICIAL DA SOCIEDADE DE PEDIATRIA DE SAO PAULO 2018; 36:221-229. [PMID: 29412431 PMCID: PMC6038783 DOI: 10.1590/1984-0462/;2018;36;2;00003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 04/14/2017] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To review findings on chemerin and factors related to cardiovascular risk in children and adolescents. DATA SOURCE A systematic review was performed, according to the standards proposed by the PRISMA guideline, on PubMed, Science Direct, and Lilacs databases. The descriptor "chemerin" was used in combination with "children" and "adolescent", no time limit applied. The research encompassed only original articles written in English, conducted with human subjects - the adult and elderly populations excluded -, as well as literature reviews, brief communications, letters, and editorials. DATA SYNTHESIS After independent analyses of the studies by two reviewers, seven articles meeting the eligibility criteria, published between 2012 and 2016, remained for the review. Cross-sectional, prospective, cohort, and case-control studies were included. The importance of chemerin adipokines on the risk factors for cardiovascular disease is demonstrated by its association with obesity and diabetes mellitus, as well as clinical, anthropometric, and biochemical parameters. However, the strength of evidence from these studies is relatively low, due to their heterogeneity, with several limitations such as small samples and consequent lack of representativeness, lack of standardization in dosage methods, cross-sectional design of most studies, and impossibility of extrapolating results. CONCLUSIONS The deregulation of chemerin caused by increased adipose tissue may contribute to the development of cardiovascular diseases, suggesting that this adipokine may play a significant role in early identification of individuals at risk.
Collapse
|
14
|
Cheon DY, Kang JG, Lee SJ, Ihm SH, Lee EJ, Choi MG, Yoo HJ, Kim CS. Serum Chemerin Levels are Associated with Visceral Adiposity, Independent of Waist Circumference, in Newly Diagnosed Type 2 Diabetic Subjects. Yonsei Med J 2017; 58:319-325. [PMID: 28120562 PMCID: PMC5290011 DOI: 10.3349/ymj.2017.58.2.319] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 10/18/2016] [Accepted: 11/10/2016] [Indexed: 01/20/2023] Open
Abstract
PURPOSE Chemerin has been suggested to be linked to insulin resistance and type 2 diabetes mellitus (T2DM). However, the relationship between visceral adiposity and chemerin levels remains unclear in subjects with T2DM. In this study, we investigated the relationship between serum chemerin levels and visceral adiposity. MATERIALS AND METHODS This study included 102 subjects newly diagnosed with T2DM. The relationships between serum chemerin levels and clinical and biochemical parameters were examined. Multiple linear regression analysis was performed to determine the predictable factors of serum chemerin levels. RESULTS Serum chemerin levels showed significant positive correlations with body mass index (BMI), waist circumference (WC), visceral fat thickness (VFT), insulin levels, the homeostasis model assessment of insulin resistance, and levels of triglycerides (log-transformed) and high-sensitivity C-reactive protein, while showing significant negative correlations with high-density lipoprotein cholesterol. After adjusting for BMI and WC, VFT showed a significant relationship with serum chemerin levels (r=0.222, p=0.027). Moreover, VFT was an independent predictive factor of serum chemerin levels (β=0.242, p=0.041). CONCLUSION We demonstrated that chemerin is linked to metabolic syndrome components. Moreover, serum chemerin levels were associated significantly with obesity, especially visceral adipose tissue, in subjects with T2DM.
Collapse
Affiliation(s)
- Dae Young Cheon
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
| | - Jun Goo Kang
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
| | - Seong Jin Lee
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
| | - Sung Hee Ihm
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
| | - Eun Jig Lee
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
| | - Moon Gi Choi
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
| | - Hyung Joon Yoo
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
| | - Chul Sik Kim
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
| |
Collapse
|